lenalidomide has been researched along with B-Cell Lymphoma in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (17.24) | 29.6817 |
| 2010's | 21 (72.41) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, H; Liu, X; Liu, Y; Wang, H; Yang, J; Zhou, K | 1 |
| Kuruvilla, J | 1 |
| Bescher, N; Bezier, I; Chouteau, M; Dulong, J; Fest, T; Houot, R; Latour, M; Ménard, C; Morschhauser, F; Nguyen, TT; Papa, I; Rossille, D; Tarte, K | 1 |
| Christos, PJ; Demetres, M; Hammad, H; Leonard, JP; Ruan, J; Yamshon, S | 1 |
| Bouabdallah, K; Cartron, G; Fabiani, B; Houot, R; Le Gouill, S; Ménard, C; Morschhauser, F; Salles, G; Tarte, K; Thieblemont, C; Tilly, H | 1 |
| Nastoupil, LJ | 1 |
| von Keudell, G; Younes, A | 1 |
| Bailly, S; Bijou, F; Bonnet, C; Bouabdallah, R; Canioni, D; Cartron, G; Feugier, P; Fruchart, C; Haioun, C; Houot, R; Le Gouill, S; Meignin, V; Morschhauser, F; Nicolas-Virelizier, E; Salles, GA; Snauwaert, S; Thieblemont, C; Tilly, H; Van Eygen, K; Wu, KL | 1 |
| Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
| Ahmadi, T; Aqui, NA; Chong, EA; Gordon, A; Mato, AR; Nasta, SD; Schuster, SJ; Svoboda, J | 1 |
| Blum, KA; Maddocks, K | 1 |
| Badillo, M; Cai, Q; Chen, Y; Huang, H; Jiang, W; Lin, T; Lopez, E; Romaguera, J; Wang, M; Zhang, L; Zhou, S; Zou, D | 1 |
| Ahmadi, T; Aqui, NA; Chong, EA; Mato, AR; Nasta, SD; Schuster, SJ; Svoboda, J; Walsh, KM | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Fowler, N; Gribben, JG; Morschhauser, F | 1 |
| Ar, MC; Salihoglu, A; Soysal, T | 1 |
| Aiba, K; Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Nagasaki, E | 1 |
| Berardi Vilei, S; Cairoli, A; Caspar, CB; Eckhardt, K; Enoiu, M; Fischer, N; Hitz, F; Krasniqi, F; Mach, N; Mey, U; Pabst, T; Rondeau, S; Rothermundt, C; Samaras, P; Schmidt, A; Zucca, E | 1 |
| Martin, P; Ruan, J; Schuster, SJ; Shah, B | 1 |
| Bouabdallah, R; Coso, D; Garciaz, S; Schiano de Colella, JM | 1 |
| Ervin-Haynes, A; Habermann, TM; Justice, G; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB | 1 |
| Bari, A; Civallero, M; Cosenza, M; Sacchi, S | 1 |
| Ohmachi, K | 1 |
| Bari, A; Civallero, M; Cosenza, M; Grisendi, G; Marcheselli, L; Roat, E; Sacchi, S | 1 |
| Ogura, M | 1 |
| Darabi, K; Kantamnei, S; Wiernik, PH | 1 |
| Brady, HA; Chan, KW; Chen, R; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Lopez-Girona, A; Moutouh-de Parseval, L; Mueller, JH; Muller, GW; Schafer, PH; Verhelle, D; Wong, K | 1 |
| Habermann, T; Menon, S; Witzig, T | 1 |
9 review(s) available for lenalidomide and B-Cell Lymphoma
| Article | Year |
|---|---|
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.
Topics: Humans; Immunologic Factors; Immunomodulating Agents; Lenalidomide; Lymphoma, B-Cell; Multiple Myeloma; Tumor Microenvironment | 2022 |
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Multiple Myeloma; Venous Thromboembolism | 2018 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bortezomib; Cytokines; Dendritic Cells; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Hematopoiesis; Humans; Killer Cells, Natural; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Peptide Hydrolases; Rituximab; T-Lymphocytes; Thalidomide; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2015 |
Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
Topics: Angiogenesis Inhibitors; B-Lymphocytes; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Signal Transduction; Thalidomide | 2015 |
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide for the treatment of B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Thalidomide | 2016 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
10 trial(s) available for lenalidomide and B-Cell Lymphoma
| Article | Year |
|---|---|
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.
Topics: Humans; Immunomodulation; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular | 2021 |
An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local | 2018 |
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents, Immunological; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Neutropenia; Recurrence; Survival Rate; Treatment Outcome | 2019 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Stem Cell Transplantation; Thalidomide | 2014 |
Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Genotype; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Grading; Receptors, IgG; Retreatment; Rituximab; T-Lymphocytes, Regulatory; Thalidomide; Treatment Outcome; Tumor Burden | 2015 |
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Thalidomide | 2016 |
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Treatment Outcome | 2009 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
10 other study(ies) available for lenalidomide and B-Cell Lymphoma
| Article | Year |
|---|---|
Developing anti-CD19 antibody-based combinations in lymphoma.
Topics: Antigens, CD19; Humans; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Prospective Studies | 2020 |
Next-generation therapy for follicular lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular | 2018 |
Will GALEN become more RELEVANT?
Topics: Antibodies, Monoclonal, Humanized; Humans; Lenalidomide; Lymphoma, B-Cell; Tomography, X-Ray Computed | 2019 |
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Rituximab; Thalidomide; Up-Regulation | 2016 |
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Indoles; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Rituximab; Thalidomide | 2011 |
Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Synergism; Humans; Indoles; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2012 |
Lenalidomide-induced warm autoimmune hemolytic anemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2006 |
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; B-Lymphocytes; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Hematopoietic Stem Cells; Humans; Lenalidomide; Lymphoma, B-Cell; Phosphorylation; Retinoblastoma Protein; Thalidomide; Up-Regulation | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Lenalidomide-associated hypothyroidism.
Topics: Antineoplastic Agents; Female; Humans; Hypothyroidism; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Thalidomide | 2007 |